Skip to main content

6 Result(s)

within Paula Cramer Remove this filter Medicine/Public Health, general Remove this filter

and

  1. Article

    Open Access

    Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

    Julia von Tresckow, Paula Cramer, Sandra Robrecht, Petra Langerbeins… in Leukemia (2022)

    Download PDF (432 KB) View Article

  2. No Access

    Article

    Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

    Moritz Fürstenau, Georg Hopfinger, Sandra Robrecht, Anna-Maria Fink… in Leukemia (2020)

  3. Article

    Open Access

    The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

    Karl-Anton Kreuzer, Richard R. Furman, Stephan Stilgenbauer, Ronald L. Dubowy… in Leukemia (2020)

    Download PDF (652 KB) View Article

  4. No Access

    Article

    CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

    Obinutuzumab (GA101) and ibrutinib show excellent efficacy for treatment of chronic lymphocytic leukemia (CLL). Preclinical investigations and a complementary safety profile were in support of testing their co...

    Julia von Tresckow, Paula Cramer, Jasmin Bahlo, Sandra Robrecht… in Leukemia (2019)

  5. No Access

    Article

    New therapeutic targets and treatment strategies

    2011 saw improvements in our understanding of B-cell malignancies: insights into the genomic basis of chronic lymphocytic leukemia were achieved; reduced treatment intensity caused fewer toxic effects in early...

    Paula Cramer, Michael Hallek in Nature Reviews Clinical Oncology (2012)

  6. No Access

    Article

    Prognostic factors in chronic lymphocytic leukemia—what do we need to know?

    Chronic lymphocytic leukemia (CLL) can present as an acute leukemia that is aggressive and life threatening or in an indolent form that will not require treatment over decades. A number of methods are availabl...

    Paula Cramer, Michael Hallek in Nature Reviews Clinical Oncology (2011)